Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma

Chemotherapy for advanced gastric and gastroesophageal junction carcinomas remains suboptimal. Both irinotecan (Camptosar) and cisplatin (Platinol) ar e active against this group of malignancies. This article focuses on the re sults of an ongoing phase II trial with this combination in patients with a dvanced gastric or gastroesophageal junction carcinoma. Data from this tria l suggest that the combination of irinotecan and cisplatin is active in unt reated as well as previously treated patients with gastric or gastroesophag eal junction carcinoma.